A0A2R9BI00 (A0A2R9BI00_PANPA) Pan paniscus (Pygmy chimpanzee) (Bonobo)
Cyclin dependent kinase inhibitor 1A UniProtKBInterProSTRINGInteractive Modelling
164 aa; Sequence (Fasta) ;
4 identical sequences: Homo sapiens: P38936; Pan troglodytes: A0A2J8NZ87, H2QSW8; Gorilla gorilla gorilla: G3RSN6
It is possible new templates exist for this target since these models were created.
Available Structures
13 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of CDK4 in complex with CyclinD1 and P21 |
Heteromer P11802; P24385; P38936; | |||||
| Assess | ||||||
| Crystal structure of the human sliding clamp at 2.0 angstrom resolution |
Heteromer P12004; P38936; | |||||
| Assess | ||||||
| Human PCNA variant (S228I) complexed with p21 at 1.9 Angstroms |
Heteromer P12004; P38936; | |||||
| Assess | ||||||
| HUMAN PCNA |
Heteromer P12004; P38936; | |||||
| Assess | ||||||
| PCNA bound to truncated peptide mimetic |
Heteromer P12004; P38936; | |||||
| Assess | ||||||
| afupcna bound with peptide mimetic |
Heteromer A0A229Y5V5; P38936; | |||||
| Assess | ||||||
| PCNA bound to peptide mimetic |
Heteromer P12004; P38936; | |||||
| Assess | ||||||
| Crystal structure of Proliferating cellular nuclear antigen 1 and Short peptide from human P21 |
Heteromer P38936; Q9M7Q7; | 3×SO4; | ||||
| Assess | ||||||
| Crystal structure of Proliferating cell nuclear antigen 2 and Short peptide from human P21 |
Heteromer P38936; Q9ZW35; | 3×SO4; | ||||
| Assess | ||||||
| PCNA in complex with inhibitor |
Heteromer P12004; P38936; | |||||
| Assess | ||||||
| Solution structure of a 14mer fragment of the p21 protein | monomer | |||||
| Assess | ||||||
| Lactam cyclised mimetic of a fragment of p21 | monomer | |||||
| Assess | ||||||
| Lactam cyclised mimetic of a fragment of p21 | monomer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6p8h.1.C | monomer | 0.56 | 100.00 | |||
| Assess | ||||||